Is this a consulting service?

No, this is a free, interactive software tool that calculates your potential liability under the DPDP Act 2023 in 30 seconds. It provides an instant risk score and automated action plan.

What are common DPDP violations in Pharma Data Compliance in Hyderabad: Avoiding DPDP Penalties?

Common violations include: Processing patient health records or clinical trial participant data without explicit, purpose-specific digital consent., Retaining clinical trial participant data beyond its necessary purpose without re-consent or proper de-identification/anonymization., Sharing patient data with third-party research labs or marketing firms without a robust Data Processing Agreement (DPA) and clear, auditable consent..

The DPDP Audit Tool

Compliance for Pharma Data Compliance in Hyderabad: Avoiding DPDP Penalties

💊

Pharma Data Compliance in Hyderabad: Avoiding DPDP Penalties
Liability Check

In Hyderabad's bustling pharma sector, mishandling health data isn't just unethical, it's a direct path to DPDP penalties up to ₹250 Crore. Clinical trial data, patient prescriptions, and R&D insights are now under intense scrutiny.

Why Pharma Data Compliance in Hyderabad: Avoiding DPDP Penalties is at Risk

Pharma companies in Hyderabad, from major players like Dr. Reddy's to emerging biotechs in Genome Valley, process vast amounts of **Sensitive Personal Data (SPD)**, including health records, genetic data, and clinical trial results. The DPDP Act mandates stringent consent, purpose limitation, and data retention policies for this data. Imagine an API manufacturer sharing anonymized patient data with a research partner, only to find it re-identifiable – that’s a massive **breach of 'purpose limitation'** and could trigger severe fines. Even legacy patient databases or clinical trial repositories not updated for DPDP compliance represent significant risk, as **Data Principals (patients)** now have strong rights, including the right to access, correction, and erasure.

Common Violations

1.Processing patient health records or clinical trial participant data without explicit, purpose-specific digital consent.
2.Retaining clinical trial participant data beyond its necessary purpose without re-consent or proper de-identification/anonymization.
3.Sharing patient data with third-party research labs or marketing firms without a robust Data Processing Agreement (DPA) and clear, auditable consent.

The Immediate Fix

Conduct an immediate data mapping exercise for all patient, trial, and employee health data within your Hyderabad facilities. Identify all instances of **Sensitive Personal Data (SPD)** and verify a legal basis for processing (primarily consent). Prioritize implementing a robust consent management system to capture and manage explicit, granular consent for all future and ongoing data processing activities.